Interventions for Tuberculosis Control and Elimination 2002

828. Orme I, Collins FM. Efficacy of Mycobacterium bovis BCG vaccination in mice
undergoing prior pulmonary infection with atypical mycobacteria.
1984; 44: 28-32.
Infect Immun
829. Brown CA, Brown IN, Swinburne S. The effect of oral Mycobacterium vaccae on
subsequent responses of mice to BCG sensitization. Tubercle 1985; 66: 251-60.
830. Comstock GW, Edwards PQ. An American view of BCG vaccination, illustrated
by results of a controlled trial in Puerto Rico.
207-17.
Scand J Respir Dis 1972; 53:
831. Fine PEM, Sterne JAC, Ponnighaus JM, Rees RJW. Delayed-type hypersensitivity,
mycobacterial vaccines and protective immunity. Lancet 1994; 344: 1245-9.
832. Fine PEM. Variation in protection by BCG: implications of and for heterologous
immunity. [Published erratum appears in Lancet 1996; 347: 340]. Lancet
1995; 346: 1339-45.
833. Romanus V, Hallander HO, Whälén P, Olinder-Nielsen AM, Magnusson PHW,
Juhlin I. Atypical mycobacteria in extrapulmonary disease among children.
Incidence in Sweden from 1969 to 1990, related to changing BCG vaccination
coverage. Tubercle Lung Dis 1995; 76: 300-10.
834. Tala E, Romanus V, Tala-Heikkilä M. Bacille Calmette-Guérin vaccination in
the 21st century. Eur Respir Mon 1997; 4: 327-53.
835. Trnka L, Dankova D, Svandová E. Six years’ experience with the discontinuation
of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium
avium intracellulare complex. Tubercle Lung Dis 1994; 75: 348-52.
836. Elias D, Wolday D, Akuffo H, Petros B, Bronner B, Britton S. Effect of deworming
on human T cell responses to mycobacterial antigens in helminth-exposed
individuals before and after bacille Calmette-Guérin (BCG) vaccination.
Exp Immunol 2001; 123: 219-25.
Clin
837. Tala-Heikkilä M. Evaluation of the Finnish BCG-revaccination programme in
schoolchildren. Ann Univ Turkuensis 1993; 119: 5-65.
838. Tala-Heikkilä M, Tuominen JE, Tala EOJ. Bacillus Calmette-Guérin revaccination
questionable with low tuberculosis incidence.
1998; 157: 1324-7.
Am J Respir Crit Care Med
839. Fine PEM. BCG vaccination against tuberculosis and leprosy. Br Med Bull
1988; 44: 691-703.
840. Smith PG, Revill WDL, Lukwago E, Rykushin YP. The protective effect of
BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic
area of Uganda. Trans R Soc Trop Med Hyg 1976; 70: 449-57.
841. Anonymous.
337: 821-2.
Topical BCG for recurrent superficial bladder cancer. Lancet 1991;
842. Melekos MD, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G,
Dauaher H. Intravesical Bacillus Calmette-Guérin immunoprophylaxis of superficial
bladder cancer: results of a controlled prospective trial with modified treatment
schedule. J Urology 1993; 149: 744-8.
225